Glistenings and PCO Evaluation for the Envista MX60

Democritus University of Thrace60 enrolled

Overview

Posterior capsule opacification (PCO) and glistenings development is among the primary reasons for sub-optimal visual capacity following cataract extraction surgery. Primary objective of this study is to evaluate the incidence of PCO and glistenings of the popular envista MX-60 intraocular lens (Bausch + Lomb) in a random sample of cataract patients who underwent phacoemulsification at least 1 year prior to their enrollment at the study

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cataract

Interventions

PhacoemulsificationPROCEDURE

Phacoemulsification for cataract extraction with Envista MX-60 implantation

Eligibility

Sex: ALLMin age: 60 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Diagnosis of senile cataract with stage 3 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale Exclusion Criteria: Endothelial cell count less than 1900, glaucoma, IOP-lowering medications, former incisional surgery, former diagnosis of corneal disease, diabetes or autoimmune diseases

Outcomes

Primary Outcomes

Glistenings

Evaluation of glistenings using Scheimpflug analysis

Time frame: 1 year

Posterior capsule Opacification (PCO)

Evaluation of PCO using EPCO software

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.